What is new about primary cutaneous B cell lymphomas.

Area of Science:

• Hematology
• Dermatology
• Oncology

Background:

• Primary cutaneous B-cell lymphomas (CBCL) are a diverse group of lymphomas affecting the skin.
• The 2022 World Health Organization classification refines the categorization of CBCL subtypes.

Purpose of the Study:

• To review the clinical, cellular, and molecular characteristics of the five CBCL subtypes.
• To discuss current management and treatment strategies for CBCL.
• To highlight the need for further research in CBCL.

Main Methods:

• Literature review of recent scientific advances.
• Analysis of the 2022 World Health Organization classification of mature lymphoid neoplasms.
• Synthesis of information on clinical, cellular, and molecular features, management, and treatment.

Main Results:

• The 2022 classification distinguishes indolent CBCL (marginal zone, follicle center lymphoma, EBV-positive mucocutaneous ulcer) from aggressive CBCL (diffuse large B-cell lymphoma, leg-type, intravascular large B-cell lymphoma).
• Understanding of CBCL entities has advanced significantly.
• New treatments for systemic B-cell lymphomas offer hope for CBCL.

Conclusions:

• Accurate classification of CBCL is essential for appropriate management.
• High-quality prospective research is crucial to update international guidelines for CBCL.
• Translating advances in systemic lymphoma treatment to CBCL requires specific investigation.